Crabel Capital Management’s AbbVie ABBV Stock Holding History

Crabel Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,823	Closed	-$338K	–	5
2019 Q4	$338K	Buy	+3,823	New	+$317K	0.13%	118

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crabel Capital Management's ABBV Position: Q1 2020 in Review

Crabel Capital Management sold out of AbbVie (ABBV) in Q1 2020, closing a stake of 3,823 shares — an estimated $338K sold.

Crabel Capital Management first reported a position in ABBV in Q4 2019 and held it in 1 quarter. The position peaked at $338K in Q4 2019. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

Crabel Capital Management reported no remaining AbbVie position as of Q1 2020 after selling out during the quarter.
Crabel Capital Management sold 3,823 AbbVie shares in Q1 2020, an estimated $338K.
Crabel Capital Management first reported a position in AbbVie in Q4 2019 and held it in 1 quarter.
Crabel Capital Management's AbbVie position peaked at $338K in Q4 2019.
2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Crabel Capital Management's 13F filing for Q1 2020, filed 7 May 2020.